FORTAZ Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Fortaz, and what generic alternatives are available?
Fortaz is a drug marketed by Pai Holdings Pharm and is included in two NDAs.
The generic ingredient in FORTAZ is ceftazidime sodium. There are seventeen drug master file entries for this compound. Additional details are available on the ceftazidime sodium profile page.
Summary for FORTAZ
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 42 |
Clinical Trials: | 1 |
Patent Applications: | 8,286 |
Formulation / Manufacturing: | see details |
What excipients (inactive ingredients) are in FORTAZ? | FORTAZ excipients list |
DailyMed Link: | FORTAZ at DailyMed |
Recent Clinical Trials for FORTAZ
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University Hospital Rijeka | Phase 4 |